Home  >  News
Marketing
+ Font Resize -

Collegium Pharma to commercialize Grünenthal's Nucynta US territory

Aachen, Germany
Wednesday, December 06, 2017, 16:00 Hrs  [IST]

The Grünenthal Group, an entrepreneurial, science-based pharmaceutical company, announced that Nucynta (tapentadol) will be commercialized in the US territory by Collegium Pharmaceutical, Inc., instead of Depomed, Inc., from 2018 onwards.

In recent months, Depomed has been struggling to grow Nucynta. Depomed executes its strategy to transform into a specialty pharmaceutical company with less focus on opioids. Grünenthal has looked at various options to reinforce the performance of Nucynta, and strengthen its presence in the US. But given the dynamics in the opioid market, Grünenthal concluded and agreed that transferring Nucynta to Collegium would be the best option. This agreement should give Grünenthal a more committed partner and provides a pre-agreed fixed minimum royalty income stream over the next few years, if the partner performs within a given range of revenue achievements.

Collegium is focused on pain management developing and commercializing next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. “They are well positioned in the market and successfully increased the sales of their opioid Xtampza in a very challenging and declining US-opioid market”, Gabriel Baertschi, CEO Grünenthal Group said. Nucynta is highly synergetic for Collegium. It is a perfect fit to more effectively compete on the market, and meet the needs of patients, physicians and payors. “We believe that adding Nucynta to their portfolio will expand the continuum of care for pain patients and strengthen Collegium as a leader in pain management”, Gabriel Baertschi stated.

Collegium is strongly incentivized to make Nucynta a success by paying a fixed royalty even for sales below a certain level (between $ 180 mn and $ 243 mn), and being rewarded if they exceed the upper range of the forecast ($ 258 mn). Grünenthal will continue to receive a royalty rate based on certain net sales thresholds and will receive a fixed royalty income in the first four years, if the sales are above $ 180 mn.

This agreement contributes to Grünenthal’s financial strength and to some extent removes the uncertainties linked to the US-market development, while providing Grünenthal with a partner committed to pain management in the US.

The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. Its ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a € 2 billion company.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
PITS_2017
duphat_150x60
Pre-Connect Congress 2017
acssymposium
PHARMACONNECT_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |